Amici Clinical Research — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$6,277	107
2024	Research	$9,620	3
2023	Research	$8,368	3
2022	Research	$30,619	4
2021	Research	$28,573	2
2020	Research	$26,643	1

Breakdown

Who paid Research payments · program years 2020–2025

Novartis Pharmaceuticals Corporation $81,997 4 payments
Boehringer Ingelheim International GmbH $15,696 105 payments
Boehringer Ingelheim Pharmaceuticals, Inc. $6,799 8 payments
AbbVie, Inc. $5,608 3 payments

Studies the money was for Research payments · program years 2020–2025

An Open-Label Extension Trial of the Phase III Lipid-Lowering Trials to Assess the Effect of Long Term Dosing of Inclisiran Given As Subcutaneous Injections in Subjects With High Cardiovascular Risk and Elevated LDL-C $81,997 4 payments
Obesity Long term safety in patients with CV risk $13,988 5 payments
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD $6,277 107 payments
Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments. $5,608 3 payments
BI 767551 EX 14870 Ph III in SARS Cov 2 Preventi $2,230 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.